American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry

ASCO 2017 – AML

Although two-thirds of patients with newly diagnosed acute myeloid leukemia (AML) are tested for recurrent mutations, most do not receive the complete panel of guideline-recommended tests.

Effect of Cytarabine/Anthracycline/Crenolanib Induction on MRD in Newly Diagnosed FLT3 Mutant AML

ASCO 2017 – AML

The majority of newly diagnosed patients with acute myeloid leukemia (AML) were found to be minimal residual disease (MRD)-negative after induction with a crenolanib-containing regimen.

Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma

ASCO 2017 – CLL

A phase 1 study evaluates the efficacy and toxicity of the combination of ibrutinib and buparlisib in relapsed/refractory non-Hodgkin lymphoma. Read More ›

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy

ASCO 2017 – CLL

The phase 2 KI Intolerance Study was undertaken to assess the safety and efficacy of TGR-1202, a next-generation, highly specific PI3Kδ inhibitor, in patients with chronic lymphocytic leukemia (CLL). Read More ›

iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)

ASCO 2017 – CLL

A phase 2 study was conducted to examine the efficacy and safety of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for previously untreated patients with mutated IGHV chronic lymphocytic leukemia (CLL). Read More ›

Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL

ASCO 2017 – CLL

This phase 2 study evaluates the efficacy and safety of bendamustine and obinutuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL). Read More ›

CD19 CAR T-Cells Combined with Ibrutinib to Induce Complete Remission in CLL

ASCO 2017 – CLL

The pilot trial of anti-CD19 chimeric antigen receptor (CAR) T-cells with ibrutinib assessed complete remission in patients with chronic lymphocytic leukemia (CLL). Read More ›

Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study

ASCO 2017 – CLL

The phase 2 AIM study examined the efficacy and safety of the combination of ibrutinib and venetoclax in relapsed/refractory mantle-cell lymphoma (MCL). Read More ›

A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas

ASCO 2017 – CLL

A phase 1 study explores a combination of a novel Bruton’s tyrosine kinase (BTK) inhibitor, DTRMWXHS-12 (DTRM-12), with everolimus and pomalidomide in patients with chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. Read More ›

Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)

ASCO 2017 – CLL

The multicenter, randomized, double-blind, placebo-controlled phase 3 PERSPECTIVE study compares the progression-free survival outcomes of ibrutinib with rituximab versus placebo with rituximab in patients with treatment-naïve (TN) follicular lymphoma (FL). Read More ›

Page 20 of 33

17
18
19
20
21
22
23

Conference Coverage Proudly Presented by

American Health & Drug Benefits

Journal of Hematology Oncology Pharmacy

Journal of Oncology Navigation & Survivorship

Oncology Practice Management

Personalized Medicine in Oncology

The Oncology Nurse–APN/PA

The Oncology Pharmacist

Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications